BioCardia Inc.

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brands. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioCardia reports successful fiscal year with promising clinical trials

BioCardia Inc. had a strong fiscal year with positive clinical trial results and increased revenues. While facing challenges related to trial data and timelines, the company's diversified product pipeline and financial stability offer growth opportunities in the healthcare sector.

BioCardia advances cell therapy programs amidst financial challenges and opportunities

BioCardia's Q1 2023 performance reflects ongoing investment in innovative cell therapy platforms. While facing financial challenges, the company remains focused on advancing clinical trials and engaging with regulatory authorities. Opportunities exist for BioCardia to leverage its expertise in cell therapy for strategic partnerships and further development.

BioCardia reports Q2 progress amidst trial setback and regulatory advancements

BioCardia's Q2 performance reflects progress in cell therapy platforms and regulatory advancements.
While facing challenges with the CardiAMP trial pause, the company maintains transparency and commitment to stakeholders.
Opportunities lie in addressing trial concerns, improving financial performance, and expanding market reach.

BioCardia reports Q3 results, progresses in cell therapy trials

BioCardia's Q3 performance reflects a mix of financial challenges and promising advancements in cell therapy trials for cardiovascular diseases.
Despite setbacks like the pause in the CardiAMP trial, the company's strategic initiatives and focus on regulatory approvals signal resilience and growth potential.
With a proactive approach to trial modifications and business development, BioCardia aims to leverage opportunities for future success in the biotech sector.

BioCardia reports positive trial data and strategic growth initiatives

BioCardia's Q4 2023 earnings call highlighted positive trial data, financial performance, strategic partnerships, and regulatory advancements, positioning the company for future growth.
While facing challenges in funding, timelines, and regulatory compliance, BioCardia's focus on innovation and market expansion presents opportunities for long-term success.
Investors should monitor BioCardia's progress in advancing its cell therapy platforms, securing approvals, and navigating regulatory landscapes for insights into its growth trajectory.

BioCardia reports positive trial results and financial improvements in Q1

BioCardia's Q1 2024 performance showcased positive trial results and improved financials, setting the stage for potential regulatory submissions and commercialization strategies.
While facing challenges in regulatory discussions and trial advancements, the company remains poised to capitalize on opportunities for growth and expansion.

BioCardia reports positive Q2 earnings, advances heart failure treatments

BioCardia demonstrated improved financial performance and significant advancements in clinical trials and product development, positioning the company for future growth
While facing challenges in regulatory compliance and financial sustainability, BioCardia's strengths in innovative treatments and partnership opportunities offer avenues for expansion
The company's focus on achieving key milestones like FDA clearances and trial completions underscores its commitment to advancing cardiovascular therapies and enhancing shareholder value

BioCardia reports strong Q3 performance, eyes partnerships for growth

BioCardia's Q3 2024 performance reflects improved financials and promising advancements in their lead cell therapy programs for heart failure
The company's strengths lie in efficient capital management, pipeline progress, and successful fundraising activities, positioning them for future growth
Challenges include clinical trial outcomes, regulatory hurdles, and balancing R&D momentum with cost management, while opportunities exist in partnerships and market expansion

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

BioCardia, Inc. (NASDAQ:BCDA ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Miranda Peto – Investor Relations Peter Altman – President and Chief Executive Officer Dave McClung – Chief Financial Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Kumar Raja – Roth Capital Laura Suriel – Alliance Global Partners Operator Good day ladies and gentlemen, thank you for standing by.

BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript

BioCardia, Inc. (BCDA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago.

BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates

SUNNYVALE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.

BioCardia Reports First Quarter 2023 Business Highlights and Financial Results

SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039.

BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications

SUNNYVALE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three months ended March 31, 2023 and provide a corporate update by conference call on Wednesday, May 10, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023

SUNNYVALE, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc.  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases has made available two presentations from the “Next Generation Cardiovascular Drug Development Summit on Executing Cell and Gene Therapy for Cardiac Regeneration” which took place this week on April 26-27, 2023 in Boston, MA.

BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available

SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.

BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies

BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Kumaraguru Raja - Roth Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.

BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript

SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support Agreement.

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders:

BioCardia Letter to Shareholders

SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with certain new and existing qualified institutional buyers, institutional accredited investors and certain directors and officers of the Company (the "Investors"). Pursuant to the Purchase Agreement, the Company agreed to sell to the Investors an aggregate 2,122,017 shares of the Company's common stock at an offering price of $1.68 per share, the average of the closing share prices for the preceding five trading days.

BioCardia Announces $3.6 Million Private Placement of Common Stock

SUNNYVALE, Calif.--( BUSINESS WIRE )--BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure.

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim James Molloy - Alliance Global Partners Operator Good day, and welcome to the BioCardia 2022 Third Quarter Conference Call.

BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript

SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2022 with the United States Securities and Exchange Commission (SEC). The Company will also hold an update conference call today at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended September 30, 2022 and provide a corporate update by conference call on Wednesday, November 9, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

Clinical Leadership and Management Call to Follow Clinical Leadership and Management Call to Follow

CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting

SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.  The conference is being held on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.

BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

SUNNYVALE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald's Cell and Genetic Medicines Conference. The conference is being held in person on September 15, 2022, at the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue.

BioCardia to Participate in Cantor Fitzgerald's Cell and Genetic Medicines Conference

Adaptive Statistical Analysis Plan Recommended

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.

News for BioCardia Inc. Stock (BCDA)